Total investments could reach €70 million, of which approximately 15% in R&D and 85% in capex, that would be deployed from 2026
_256_384.jpeg)
Launched Pathology Laboratory in Vijayawada offering a wide range of best-in-class diagnostic services with over 2500+ tests
Chinook Therapeutics is a clinical-stage biopharmaceutical company with two high-value, late-stage assets in development for IgA nephropathy (IgAN), a rare, progressive chronic kidney disease
The successful outcome of this study represents an important milestone in Dr. Reddy's commitment to make highquality biosimilar products more accessible and affordable
The development and deployment of effective vaccines can help to mitigate the impact of pandemics, and we must prioritize research efforts to achieve this objective
Olverembatinib is the first and only third-generation BCR-ABL inhibitor approved in China for the treatment of adult patients with tyrosine kinase inhibitors
This fresh infusion of capital will enable ImmunoACT to fast track the additional supply of the lead candidate HCAR-19
Synexa joins CEPI’s esteemed Central Lab Network to improve global epidemic preparedness
Continues to Expand its Presence in South India
Acquisition enhances Freenome's product portfolio, including autoantibody platform with additional biomarkers important in cancer detection
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
